WST Filings — West Pharmaceutical Services, Inc. - FilingSpy
WST
West Pharmaceutical Services, Inc.
A maker of the rubber stoppers, syringe plungers, and other packaging that keep injectable medicines sterile and safe, West Pharmaceutical Services supplies drugmakers around the world with products like its NovaPure and FluroTec lines. The company was founded in 1923 in Philadelphia by Herman O. West, who started out making rubber grinding wheels for dentists before pivoting to pharmaceutical closures. During World War II, West's rubber stoppers helped mass-distribute penicillin and insulin, and the company still carries its founder's name today.
A May 2026 cyberattack disrupted global operations and compressed West Vantage margins, even as Proprietary Products gross margin reached 42.6%.
A material cyberattack in May 2026 temporarily shut down global systems and compressed margins in the West Vantage . rose 13.8% to $872.3 million and Proprietary Products expanded 2.5 points to 42.6%, driven by high-value product demand and GLP-1-related volumes. The attack has been contained and operations have fully recovered, but the incident introduces a new operational risk that the company had not previously disclosed.
Key takeaways
A material cybersecurity attack in May 2026 involved data exfiltration and system encryption, prompting a global systems shutdown that temporarily disrupted operations; the company states the attack has been contained and operations have fully recovered.
Consolidated rose 13.8% to $872.3 million, with of 12.7%, led by Proprietary Products' 15.5% organic increase driven by high-value product components and delivery devices.
Proprietary Products expanded 2.5 points to 42.6%, which management attributed to favorable high-value product mix including GLP-1 products and sales price increases.
Section summaries
Management's Discussion and Analysis
Q2 FY2026 consolidated net sales rose 13.8% to $872.3M, driven by Proprietary Products HVP demand, while West Vantage margins fell due to a cyber incident.
⌄
Consolidated grew 13.8% to $872.3M, with of 12.7%, led by Proprietary Products' 15.5% organic increase driven by HVP components and delivery devices.
Proprietary Products expanded 2.5pp to 42.6% on favorable HVP mix including GLP-1 products and price increases, while West Vantage margin contracted 3.3pp to 14.2% due to cyber-related production downtime and inflation.
West Vantage contracted 3.3 points to 14.2%, driven by production downtime from the cyber incident and inflationary costs.
rose 16.5% to $179.1 million, while adjusted operating profit reached $197.4 million with a 22.6% margin, excluding $18.3 million in unallocated items including M&A costs and a .
fell $92.6 million to $213.9 million, driven by changes and higher annual incentive compensation payouts; cash and equivalents declined to $435.8 million after $454.3 million in share repurchases during the first half.
What changed
Proprietary Products reached 42.6%, exceeding the 40.5% full-year FY2025 level and confirming that the recovery from the 32.8% trough in Q2 2024 has continued to expand rather than merely stabilize.
The cyberattack disclosed in this filing is a new material risk that was absent from all prior filings; it introduces operational disruption as a near-term , particularly for the West Vantage , and adds ongoing costs from professional fees and mitigation efforts.
The securities class action motion to dismiss, flagged in prior filings, was fully briefed as of March 31, 2026, with no ruling yet; the company continues to state it cannot estimate a potential loss.
No update was provided on the Daikyo license renewal negotiations, which remain a watch item with the 2027 expiration approaching.
What to watch
West Vantage in Q3 2026: whether the 14.2% level rebounds now that the cyberattack has been contained and production has fully recovered, or whether lingering effects persist.
conversion: whether the $213.9 million in first-half operating cash flow improves in the second half as normalizes, or whether the current pace constrains the program.
Securities class action ruling: any decision on the fully briefed motion to dismiss, which would signal the potential financial exposure from the suit.
Daikyo license renewal: any update on negotiations for the agreements expiring in 2027, which would signal the future of the Crystal Zenith and FluroTec proprietary platforms.
Consolidated rose 16.5% to $179.1M; adjusted operating profit reached $197.4M with a 22.6% margin, excluding $18.3M in unallocated items like M&A costs and a .
SG&A costs increased 22.6% to $117.6M, driven by $12.4M higher corporate unallocated costs from nonrecurring professional fees (cyber incident, legal) and M&A expenses, plus higher .
decreased $92.6M to $213.9M due to changes and higher incentive payments; cash and equivalents fell to $435.8M after $454.3M in share repurchases.
The company does not expect material impacts from tariffs or the Middle East conflict on 2026 results, and its Israel facilities operated without material disruption.
Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in our exposure to market risk or the information provided in Part II, Item 7A of our 2025 Annual Report. 42 Table of Contents
⌄
There have been no material changes in our exposure to market risk or the information provided in Part II, Item 7A of our 2025 Annual Report.
42
Table of Contents
A securities class action is pending; the company believes claims are meritless and cannot yet estimate any loss.
⌄
A class action was filed on May 5, 2025, alleging securities law violations related to public statements and officer stock transactions.
The proposed class covers investors who purchased common stock between February 16, 2023 and February 12, 2025.
An amended complaint was filed on October 15, 2025, and defendants moved to dismiss on December 18, 2025.
The motion to dismiss is fully briefed as of March 31, 2026; the company intends to vigorously defend.
The company states it cannot reasonably estimate any loss or assess the probability of an unfavorable outcome at this early stage.
Other ordinary-course proceedings are not expected to have a material adverse effect, though an unfavorable ruling in any specific case could materially impact a particular period.
A disclosed May 2026 material cyberattack exfiltrated data and encrypted systems, temporarily disrupting global operations.
⌄
In May 2026, the company suffered a material cybersecurity attack involving data exfiltration and system encryption, prompting a global systems shutdown for containment.
The incident temporarily disrupted global operations; the company states the attack has been contained and operations have fully recovered.
Cyber threats are increasing in frequency, sophistication, and intensity, including from state-sponsored actors using evolving techniques such as artificial intelligence.
The company may not detect all incidents or respond promptly, and future attacks could cause financial loss, reputational harm, or regulatory penalties.
Cybersecurity insurance may not cover all losses, and mitigation costs are significant and expected to rise.